Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011, Article ID 639074, 8 pages
http://dx.doi.org/10.1155/2011/639074
Review Article

Pathological Role of Tonsillar B Cells in IgA Nephropathy

Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan

Received 30 January 2011; Accepted 17 May 2011

Academic Editor: K. Blaser

Copyright © 2011 Yusuke Suzuki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. F. M. Strippoli, A. Maione, F. P. Schena, G. Tognoni, and J. C. Craig, “IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice,” American Journal of Kidney Diseases, vol. 53, no. 1, pp. 5–8, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. Barratt and J. Feehally, “IgA nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2088–2097, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. Floege, M. Burg, and V. Kliem, “Recurrent IgA nephropathy after kidney transplantation: not a benign condition,” Nephrology Dialysis Transplantation, vol. 13, no. 8, pp. 1933–1935, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Cuevas, J. Lloveras, M. Mir, J. Aubia, and J. Masramon, “Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation,” Transplantation Proceedings, vol. 19, no. 1, pp. 2208–2209, 1987. View at Google Scholar · View at Scopus
  5. F. Sanfilippo, B. P. Croker, and R. R. Bollinger, “Fate of four cadaveric donor renal allografts with mesangial IgA deposits,” Transplantation, vol. 33, no. 4, pp. 370–376, 1982. View at Google Scholar · View at Scopus
  6. Y. Suzuki and Y. Tomino, “Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: insights from animal models,” Seminars in Nephrology, vol. 28, no. 1, pp. 66–77, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. Barratt, J. Feehally, and A. C. Smith, “Pathogenesis of IgA nephropathy,” Seminars in Nephrology, vol. 24, no. 3, pp. 197–217, 2004. View at Publisher · View at Google Scholar
  8. S. N. Emancipator, “Immunoregulatory factors in the pathogenesis of IgA nephropathy,” Kidney International, vol. 38, no. 6, pp. 1216–1229, 1990. View at Google Scholar · View at Scopus
  9. J. W. de Fijter, J. W. Eijgenraam, C. A. Braam et al., “Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nepbropathy,” Kidney International, vol. 50, no. 3, pp. 952–961, 1996. View at Google Scholar · View at Scopus
  10. J. I. Roodnat, J. W. de Fijter, C. van Kooten, M. R. Daha, and L. A. Van Es, “Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy,” Nephrology Dialysis Transplantation, vol. 14, no. 2, pp. 353–359, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Xie, S. Nishi, M. Ueno et al., “The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy,” Kidney International, vol. 63, no. 5, pp. 1861–1867, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Sato, O. Hotta, S. Tomioka et al., “Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy,” Nephron Clinical Practice, vol. 93, no. 4, pp. 137–145, 2003. View at Google Scholar · View at Scopus
  13. O. Hotta, M. Miyazaki, T. Furuta et al., “Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy,” American Journal of Kidney Diseases, vol. 38, no. 4, pp. 736–743, 2001. View at Google Scholar · View at Scopus
  14. H. Komatsu, S. Fujimoto, S. Hara, Y. Sato, K. Yamada, and K. Kitamura, “Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 5, pp. 1301–1307, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. F. M. Rasche, A. Schwarz, and F. Keller, “Tonsillectomy does not prevent a progressive course in IgA nephropathy,” Clinical Nephrology, vol. 51, no. 3, pp. 147–152, 1999. View at Google Scholar · View at Scopus
  16. A. Piccoli, M. Codognotto, M. G. Tabbi, E. Favaro, and B. Rossi, “Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis,” Nephrology Dialysis Transplantation, vol. 25, no. 8, pp. 2583–2589, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. Y. Chen, Z. Tang, Q. Wang et al., “Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy,” American Journal of Nephrology, vol. 27, no. 2, pp. 170–175, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. L. S. Ibels, A. Z. Gyory, R. J. Caterson et al., “Recognition and management of IgA nephropathy,” Drugs, vol. 55, no. 1, pp. 73–83, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Miura, H. Imai, S. Kikuchi et al., “Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy,” Clinical and Experimental Nephrology, vol. 13, no. 5, pp. 460–466, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. Kataura and H. Tsubota, “Clinical analyses of focus tonsil and related diseases in Japan,” Acta Oto-Laryngologica, no. 523, supplement, pp. 161–164, 1996. View at Google Scholar
  21. T. Ono, M. Jono, M. Kito et al., “Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris,” Acta Oto-Laryngologica, vol. 401, pp. 12–16, 1983. View at Google Scholar · View at Scopus
  22. M. Yokoyama, K. Hashiguchi, and Y. Yamasaki, “Effects of tonsillectomy in patients with pusutulosis Palmaris et plantaris,” Acta Oto-Laryngologica, vol. 124, pp. 1109–1110, 2004. View at Google Scholar
  23. K. Noda, S. Kodama, S. Suenaga, and M. Suzuki, “Tonsillar focal infectious disease involving IgA nephropathy, pustulosis, and ossification,” Clinical and Experimental Nephrology, vol. 11, no. 1, pp. 97–101, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. Y. Tomino, M. Endoh, Y. Nomoto, and H. Sakai, “Immunoglobulin A1 and IgA nephropathy,” New England Journal of Medicine, vol. 305, no. 19, pp. 1159–1160, 1981. View at Google Scholar · View at Scopus
  25. A. W. L. van den Wall Bake, J. Evers-Schouten, and L. A. van Es, “Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: evidence for the bone marrow as the source of mesangial IgA,” American Journal of Kidney Diseases, vol. 12, no. 5, pp. 410–414, 1988. View at Google Scholar · View at Scopus
  26. O. Sakai, “IgA nephropathy: current concepts and feature trends,” Nephrology, vol. 3, pp. 2–3, 1997. View at Google Scholar
  27. Y. Iwata, T. Wada, A. Uchiyama et al., “Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia,” Internal Medicine, vol. 45, no. 22, pp. 1291–1295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Layward, A. M. Finnemore, A. C. Allen, S. J. Harper, and J. Feehally, “Systemic and mucosal IgA responses to systemic antigen challenge in IgA nephropathy,” Clinical Immunology and Immunopathology, vol. 69, no. 3, pp. 306–313, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. A. W. van den Wall Bake, W. E. Beyer, J. H. Evers-Schouten et al., “Humoral immune response to influenza vaccination in patients with primary immunoglobulin A nephropathy. An analysis of isotype distribution and size of the influenza-specific antibodies,” Journal of Clinical Investigation, vol. 84, no. 4, pp. 1070–1075, 1989. View at Google Scholar · View at Scopus
  30. M. C. Bene, G. Faure, B. H. de Ligny et al., “Immunoglobulin A nephropathy. Quantitative immunohistomorphometry of the tonsillar plasma cells evidences an inversion of the immunoglobulin A versus immunoglobulin G secreting cell balance,” Journal of Clinical Investigation, vol. 71, no. 5, pp. 1342–1347, 1983. View at Google Scholar · View at Scopus
  31. S. J. Harper and J. Feehally, “The pathogenic role of immunoglobulin A polymers in immunoglobulin A nephropathy,” Nephron, vol. 65, no. 3, pp. 337–345, 1993. View at Google Scholar · View at Scopus
  32. C. Kusakari, M. Nose, T. Takasaka et al., “Immunopathological features of palatine tonsil characteristic of IgA nephropathy: IgA1 localization in follicular dendritic cells,” Clinical and Experimental Immunology, vol. 95, no. 1, pp. 42–48, 1994. View at Google Scholar · View at Scopus
  33. S. J. Harper, J. H. Pringle, A. C. B. Wicks et al., “Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy,” Kidney International, vol. 45, no. 3, pp. 836–844, 1994. View at Google Scholar · View at Scopus
  34. A. W. van den Wall Bake, M. R. Daha, and L. A. van Es, “Immunopathogenetic aspects of IgA nephropathy,” Nephrologie, vol. 10, no. 3, pp. 141–145, 1989. View at Google Scholar · View at Scopus
  35. L. A. van Es, A. W. van den Wall Bake, R. K. Stad, M. E. van den Dobbelsteen, M. J. Bogers, and M. R. Daha, “Enigmas in the pathogenesis of IgA nephropathy,” Contributions to Nephrology, vol. 111, pp. 169–175, 1995. View at Google Scholar
  36. E. J. Kunkel and E. C. Butcher, “Plasma-cell homing,” Nature Reviews Immunology, vol. 3, no. 10, pp. 822–829, 2003. View at Google Scholar · View at Scopus
  37. Z. Moldoveanu, R. J. Wyatt, J. Y. Lee et al., “Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels,” Kidney International, vol. 71, no. 11, pp. 1148–1154, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. H. Suzuki, Z. Moldoveanu, S. Hall et al., “IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 629–639, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. R. J. Glassock, “Analyzing antibody activity in IgA nephropathy,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1450–1452, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Hiki, H. Odani, M. Takahashi et al., “Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy,” Kidney International, vol. 59, no. 3, pp. 1077–1085, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. A. C. Allen, E. M. Bailey, P. E. C. Brenchley, K. S. Buck, J. Barratt, and J. Feehally, “Mesangial Iga1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients,” Kidney International, vol. 60, no. 3, pp. 969–973, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. T. Kokubo, Y. Hiki, H. Iwase et al., “Protective role of IgA1 glycans against IgA1 self- aggregation and adhesion to extracellular matrix proteins,” Journal of the American Society of Nephrology, vol. 9, no. 11, pp. 2048–2054, 1998. View at Google Scholar · View at Scopus
  43. J. Novak, B. A. Julian, M. Tomana, and J. Mestecky, “IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy,” Seminars in Nephrology, vol. 28, no. 1, pp. 78–87, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. Y. Hiki, “O-linked oligosaccharides of the IgA1 hinge region: roles of its aberrant structure in the occurrence and/or progression of IgA nephropathy,” Clinical and Experimental Nephrology, vol. 13, no. 5, pp. 415–423, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. J. Novak, M. Tomana, K. Matousovic et al., “IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells,” Kidney International, vol. 67, no. 2, pp. 504–513, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. J. Novak, H. L. Vu, L. Novak, B. A. Julian, J. Mestecky, and M. Tomana, “Interactions of human mesangial cells with IgA and IgA-containing immune complexes,” Kidney International, vol. 62, no. 2, pp. 465–475, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. C. Gómez-Guerrero, E. González, and J. Egido, “Evidence for a specific IgA receptor in rat and human mesangial cells,” Journal of Immunology, vol. 151, no. 12, pp. 7172–7181, 1993. View at Google Scholar · View at Scopus
  48. C. Gómez-Guerrero, M. J. López-Armada, E. González, and J. Egido, “Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-α and IL-6, and proliferation,” Journal of Immunology, vol. 153, no. 11, pp. 5247–5256, 1994. View at Google Scholar · View at Scopus
  49. P. J. M. van der Boog, C. van Kooten, J. W. de Fijter, and M. R. Daha, “Role of macromolecular IgA in IgA nephropathy,” Kidney International, vol. 67, no. 3, pp. 813–821, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. J. Mestecky, M. Tomana, P. A. Crowley-Nowick, Z. Moldoveanu, B. A. Julian, and S. Jackson, “Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy,” Contributions to Nephrology, vol. 104, pp. 172–182, 1993. View at Google Scholar · View at Scopus
  51. R. Coppo and A. Amore, “Aberrant glycosylation in IgA nephropathy (IgAN),” Kidney International, vol. 65, no. 5, pp. 1544–1547, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. A. Horie, Y. Hiki, H. Odani et al., “IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy,” American Journal of Kidney Diseases, vol. 42, no. 3, pp. 486–496, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Itoh, H. Iwase, T. Takatani et al., “Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients,” Nephrology Dialysis Transplantation, vol. 18, no. 6, pp. 1108–1114, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Iwanami, H. Iwase, N. Takahashi et al., “Similarities between N-glycan glycoform of tonsillar IgA1 and that of aberrant IgA1 abundant in IgA nephropathy patient serum,” Journal of Nephrology, vol. 21, no. 1, pp. 118–126, 2008. View at Google Scholar · View at Scopus
  55. T. Inoue, H. Sugiyama, Y. Hiki et al., “Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy,” Clinical Immunology, vol. 136, no. 3, pp. 447–455, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. R. C. Monteiro and J. G. J. Van De Winkel, “IgA Fc receptors,” Annual Review of Immunology, vol. 21, pp. 177–204, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. T. Nishie, O. Miyaishi, H. Azuma et al., “Development of immunoglobulin A nephropathy-like disease in β-1,4-galactosyltransferase-I-deficient mice,” American Journal of Pathology, vol. 170, no. 2, pp. 447–456, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. I. Kobayashi, F. Nogaki, H. Kusano et al., “Interleukin-12 alters the physicochemical characteristics of serum and glomerular IgA and modifies glycosylation in a ddY mouse strain having high IgA levels,” Nephrology Dialysis Transplantation, vol. 17, no. 12, pp. 2108–2116, 2002. View at Google Scholar · View at Scopus
  59. R. J. Glassock, “IgA nephropathy: challenges and opportunities,” Cleveland Clinic Journal of Medicine, vol. 75, no. 8, pp. 569–576, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. G. Gharavi, Z. Moldoveanu, R. J. Wyatt et al., “Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 5, pp. 1008–1014, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. H. Suzuki, R. Fan, Z. Zhang et al., “Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1668–1677, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. J. Barratt, F. Eitner, J. Feehally, and J. Floege, “Immune complex formation in IgA nephropathy: a case of the ‘right’ antibodies in the ‘wrong’ place at the ‘wrong’ time,” Nephrology Dialysis Transplantation, vol. 24, no. 12, pp. 3620–3623, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. J. Barratt and F. Eitner, “Glomerular disease: sugars and immune complex formation in IgA nephropathy,” Nature Reviews Nephrology, vol. 5, pp. 612–614, 2009. View at Google Scholar
  64. H. Suzuki, Y. Suzuki, M. Aizawa et al., “Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells,” Kidney International, vol. 72, no. 3, pp. 319–327, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. P. O. Leinikki, J. Mustonen, and A. Pasternack, “Immune response to oral polio vaccine in patients with IgA glomerulonephritis,” Clinical and Experimental Immunology, vol. 68, no. 1, pp. 33–38, 1987. View at Google Scholar · View at Scopus
  66. S. N. Emancipator, G. R. Gallo, and M. E. Lamm, “Experimental IgA nephropathy induced by oral immunization,” Journal of Experimental Medicine, vol. 157, no. 2, pp. 572–582, 1983. View at Google Scholar · View at Scopus
  67. R. Coppo, B. Basolo, and C. Rollino, “Mediterranean diet and primary IgA nephropathy,” Clinical Nephrology, vol. 26, no. 2, pp. 72–82, 1986. View at Google Scholar · View at Scopus
  68. V. Kumar, M. Sieniawska, E. H. Beutner, and T. P. Chorzelski, “Are immunological markers of gluten-sensitive enteropathy detectable in IgA nephropathy?” The Lancet, vol. 2, no. 8623, p. 1307, 1988. View at Google Scholar · View at Scopus
  69. A. Fornasieri, R. A. Sinico, P. Maldifassi et al., “IgA-Antigliadin antibodies in IgA mesangial nephropathy (Berger's disease),” British Medical Journal, vol. 295, no. 6590, pp. 78–80, 1987. View at Google Scholar · View at Scopus
  70. G. Rostoker, J. Laurent, C. André, S. Cholin, and G. Lagrue, “High levels of IgA antigliadin antibodies in patients who have IgA mesangial glomerulonephritis but not coeliac disease,” The Lancet, vol. 1, no. 8581, pp. 356–357, 1988. View at Google Scholar · View at Scopus
  71. R. Coppo, G. Mazzucco, G. Martina et al., “Gluten-induced experimental IgA glomerulopathy,” Laboratory Investigation, vol. 60, no. 4, pp. 499–506, 1989. View at Google Scholar · View at Scopus
  72. D. Yan, W. K. Rumbeiha, and J. J. Pestka, “Experimental murine IgA nephropathy following passive administration of vomitoxin-induced IgA monoclonal antibodies,” Food and Chemical Toxicology, vol. 36, no. 12, pp. 1095–1106, 1998. View at Publisher · View at Google Scholar · View at Scopus
  73. J. J. Pestka, “Deoxynivalenol-induced IgA production and IgA nephropathy-aberrant mucosal immune response with systemic repercussions,” Toxicology Letters, vol. 140-141, pp. 287–295, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Shi and J. J. Pestka, “Attenuation of mycotoxin-induced IgA nephropathy by eicosapentaenoic acid in the mouse: dose response and relation to IL-6 expression,” Journal of Nutritional Biochemistry, vol. 17, no. 10, pp. 697–706, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. F. Hinoshita, Y. Suzuki, K. Yokoyama et al., “Experimental IgA nephropathy induced by a low-dose environmental mycotoxin, nivalenol,” Nephron, vol. 75, no. 4, pp. 469–478, 1997. View at Google Scholar · View at Scopus
  76. H. K. Smerud, B. Fellström, R. Hällgren, S. Osagie, P. Venge, and G. Kristjánsson, “Gastrointestinal sensitivity to soy and milk proteins in patients with IgA nephropathy,” Clinical Nephrology, vol. 74, no. 5, pp. 364–371, 2010. View at Google Scholar · View at Scopus
  77. A. C. Smith, K. Molyneux, J. Feehally, and J. Barratt, “O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy,” Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3520–3528, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. H. Suzuki, Y. Suzuki, T. Yamanaka et al., “Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23,” Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1289–1299, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. S. Akira, K. Takeda, and T. Kaisho, “Toll-like receptors: critical proteins linking innate and acquired immunity,” Nature Immunology, vol. 2, no. 8, pp. 675–680, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. S. Akira and K. Takeda, “Toll-like receptor signalling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 499–511, 2004. View at Google Scholar · View at Scopus
  81. H. Suzuki, Y. Suzuki, I. Narita et al., “Toll-like receptor 9 affects severity of IgA nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 12, pp. 2384–2395, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. T. Kaisho and S. Akira, “Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice,” Trends in Immunology, vol. 22, no. 2, pp. 78–83, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. A. A. Ashkar and K. L. Rosenthal, “Toll-like receptor 9, CpG DNA and innate immunity,” Current Molecular Medicine, vol. 2, no. 6, pp. 545–556, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. E. A. Leadbetter, I. R. Rifkin, and A. Marshak-Rothstein, “Toll-like receptors and activation of autoreactive B cells,” Current Directions in Autoimmunity, vol. 6, pp. 105–122, 2003. View at Google Scholar · View at Scopus
  85. R. H. Carter and R. Myers, “Germinal center structure and function: lessons from CD19,” Seminars in Immunology, vol. 20, no. 1, pp. 43–48, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. R. D. Sanderson, P. Lalor, and M. Bernfield, “B lymphocytes express and lose syndecan at specific stages of differentiation,” Cell Regulation, vol. 1, no. 1, pp. 27–35, 1989. View at Google Scholar · View at Scopus
  87. M. Aizawa, Y. Suzuki, H. Suzuki et al., “Roles of bone marrow, mucosa and lymphoid tissues in pathogenesis of murine IgA nephropathy,” Contributions to Nephrology, vol. 157, pp. 164–168, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. R. Shinkura, F. Matsuda, T. Sakiyama et al., “Defects of somatic hypermutation and class switching in alymphoplasia (aly) mutant mice,” International Immunology, vol. 8, no. 7, pp. 1067–1075, 1996. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Masuda, S. Tamura, and N. Sugiyama, “The effect of tonsillectomy and its postoperative clinical course in IgA nephropathy with chronic tonsillitis,” Advances in Oto-Rhino-Laryngology, vol. 47, pp. 203–207, 1992. View at Google Scholar · View at Scopus
  90. Y. Masuda, K. Terazawa, S. Kawakami, Y. Ogura, and N. Sugiyama, “Clinical and immunological study of IgA nephropathy before and after tonsillectomy,” Acta Oto-Laryngologica, vol. 106, no. 454, supplement, pp. 248–255, 1988. View at Google Scholar · View at Scopus
  91. S. Tomioka, K. Miyoshi, K. Tabata, O. Hotta, and Y. Taguma, “Clinical study of chronic tonsillitis with IgA nephropathy treated by tonsillectomy,” Acta Oto-Laryngologica, no. 523, supplement, pp. 175–177, 1996. View at Google Scholar · View at Scopus
  92. D. Sato, Y. Suzuki, T. Kano et al., “Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients,” Nephrology Dialysis Transplantation, 2011. In press.
  93. T. Goto, N. Bandoh, T. Yoshizaki et al., “Increase in B-cell-activation factor (BAFF) and IFN-γ productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy,” Clinical Immunology, vol. 126, no. 3, pp. 260–269, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. S. Kodama, M. Suzuki, M. Arita, and G. Mogi, “Increase in tonsillar germinal centre B-1 cell numbers in IgA nephropathy (IgAN) patients and reduced susceptibility to Fas-mediated apoptosis,” Clinical and Experimental Immunology, vol. 123, no. 2, pp. 301–308, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. L. G. Ng, C. H. Ng, B. Woehl et al., “BAFF costimulation of Toll-like receptor-activated B-1 cells,” European Journal of Immunology, vol. 36, no. 7, pp. 1837–1846, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. K. Iio, Y. Nagasawa, H. Iwatani et al., “Microarray analysis of tonsils in immunoglobulin A nephropathy patients,” Biochemical and Biophysical Research Communications, vol. 393, no. 4, pp. 565–570, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. A. Krug, A. Towarowski, S. Britsch et al., “Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with Cd40 ligand to induce high amounts of IL-12,” European Journal of Immunology, vol. 31, no. 10, pp. 3026–3037, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Hemmi, T. Kaisho, O. Takeuchi et al., “Small-antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway,” Nature Immunology, vol. 3, no. 2, pp. 196–200, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. M. Kerkmann, S. Rothenfusser, V. Hornung et al., “Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells,” Journal of Immunology, vol. 170, no. 9, pp. 4465–4474, 2003. View at Google Scholar · View at Scopus